S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Kala Pharmaceuticals (KALA) Stock Forecast, Price & News

-0.03 (-4.43%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
607,554 shs
Average Volume
760,415 shs
Market Capitalization
$46.97 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Kala Pharmaceuticals logo

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$11.24 million
Book Value
($0.07) per share


Net Income
$-142.60 million
Net Margins
Pretax Margin




Free Float
Market Cap
$46.97 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.14 out of 5 stars

Medical Sector

442nd out of 1,416 stocks

Pharmaceutical Preparations Industry

185th out of 677 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

Is Kala Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Kala Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View analyst ratings for Kala Pharmaceuticals
or view top-rated stocks.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Kala Pharmaceuticals

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings data on Monday, May, 16th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. Kala Pharmaceuticals had a negative trailing twelve-month return on equity of 369.16% and a negative net margin of 1,552.90%. During the same quarter last year, the firm posted ($0.49) EPS.
View Kala Pharmaceuticals' earnings history

What price target have analysts set for KALA?

3 brokerages have issued 12 month price targets for Kala Pharmaceuticals' stock. Their forecasts range from $1.50 to $5.00. On average, they expect Kala Pharmaceuticals' stock price to reach $3.38 in the next twelve months. This suggests a possible upside of 421.6% from the stock's current price.
View analysts' price targets for Kala Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the following people:
  • Mr. Mark T. Iwicki, Chairman & CEO (Age 56, Pay $919.89k) (LinkedIn Profile)
  • Mr. Todd Bazemore, Pres & COO (Age 52, Pay $671.58k) (LinkedIn Profile)
  • Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer (Age 69, Pay $645.19k)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 47) (LinkedIn Profile)
  • Ms. Jill S. Steier, Exec. Director of Investor Relations & Corp. Communications
  • Mr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)
  • Ms. Kathleen McCann Kline, Sr. VP of Marketing
  • Ms. Michele LaRussa, Sr. VP of Regulatory Affairs & Quality Assurance (Age 52)
  • Mr. Vincent Kosewski, Sr. VP of Manufacturing & Supply Chain Management (Age 59)
What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?

1 employees have rated Kala Pharmaceuticals CEO Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among Kala Pharmaceuticals' employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.32%), State Street Corp (1.69%), Vahanian & Associates Financial Planning Inc. (0.80%), Graypoint LLC (0.67%), Northern Trust Corp (0.55%) and Renaissance Technologies LLC (0.36%). Company insiders that own Kala Pharmaceuticals stock include Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Romulus K Brazzell and Todd Bazemore.
View institutional ownership trends for Kala Pharmaceuticals

Which institutional investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Vahanian & Associates Financial Planning Inc., Goldman Sachs Group Inc., Northern Trust Corp, Simplex Trading LLC, UBS Group AG, and Group One Trading L.P.. Company insiders that have sold Kala Pharmaceuticals company stock in the last year include Hongming Chen, Mark T Iwicki, Mary Reumuth, Romulus K Brazzell, and Todd Bazemore.
View insider buying and selling activity for Kala Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Kala Pharmaceuticals stock?

KALA stock was purchased by a variety of institutional investors in the last quarter, including Graypoint LLC, Renaissance Technologies LLC, State Street Corp, Integrated Wealth Concepts LLC, Jane Street Group LLC, MAI Capital Management, GSA Capital Partners LLP, and Mirabella Financial Services LLP.
View insider buying and selling activity for Kala Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $0.65.

How much money does Kala Pharmaceuticals make?

Kala Pharmaceuticals has a market capitalization of $46.97 million and generates $11.24 million in revenue each year. The company earns $-142.60 million in net income (profit) each year or ($2.13) on an earnings per share basis.

How many employees does Kala Pharmaceuticals have?

Kala Pharmaceuticals employs 192 workers across the globe.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is www.kalarx.com.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at (781) 996-5252, via email at [email protected], or via fax at 781-642-0399.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.